Description: AccuStem Sciences, Inc. operates as a life sciences company focusing on improving outcomes for patients with cancer. It develops StemPrintER technology, a multi-gene prognostic assay to predict the risk of recurrence of Endocrine receptor-positive /HER2- breast cancer; and Spare, a derivative of StemPrintER that combines StemPrintER with two clinical markers. The company is based in New York, New York.
Home Page: www.accustem.com
5 Penn Plaza
New York,
NY
10001
United States
Phone:
Officers
| Name | Title |
|---|---|
| Ms. Wendy Blosser | CEO & Director |
| Mr. Jeff Fensterer | Chief Operating Officer |
| Mr. Joe Flanagan | Chief Bus. Officer |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | |
| Full Time Employees: | 0 |